Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial
2014; Oxford University Press; Volume: 35; Issue: 47 Linguagem: Inglês
10.1093/eurheartj/ehu305
ISSN1522-9645
AutoresGünter Breithardt, Helmut Baumgartner, Scott D. Berkowitz, Anne S. Hellkamp, Jonathan P. Piccini, Susanna R. Stevens, Yuliya Lokhnygina, Manesh R. Patel, Jonathan L. Halperin, Daniel E. Singer, Graeme J. Hankey, Werner Hacke, Richard C. Becker, Christopher C. Nessel, Kenneth W. Mahaffey, Keith A.A. Fox, Robert M. Califf,
Tópico(s)Venous Thromboembolism Diagnosis and Management
ResumoAimsWe investigated clinical characteristics and outcomes of patients with significant valvular disease (SVD) in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) trial.
Referência(s)